Evidence map›Paper›PMID 39829075›Full record

ArticlePharmacogenomics2024

Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study.

A A Skryabina, V V Nikiforov, M Z Shakhmardanov, M S Zastrozhin, D A Sychev

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A A SkryabinaInfectious Diseases Department, Pirogov Russian National Research Medical University, Moscow, Russia.ORCID 0000-0002-2098-222X
V V NikiforovInfectious Diseases Department, Pirogov Russian National Research Medical University, Moscow, Russia.
M Z ShakhmardanovInfectious Diseases Department, Pirogov Russian National Research Medical University, Moscow, Russia.
M S ZastrozhinDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, USA.
D A SychevDepartment of Clinical Pharmacology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMacrolides are widely used antibiotics, but adverse drug reactions (ADRs), particularly in genetically predisposed individuals, can compromise their safety. This study examines the impact of pharmacogenetic markers on macrolide safety in participants with bacterial complications of influenza.

objectiveTo evaluate how polymorphisms in genes encoding transporter proteins (ABCB1) and enzymes (CYP3A4, CYP3A5) influence ADR risk during macrolide therapy.

methodsA prospective study included 100 participants with lower respiratory tract bacterial complications of influenza treated with azithromycin or erythromycin for five days. Genotyping targeted

resultsThe

conclusionGenetic polymorphisms in

Indexed as

Anti-Bacterial AgentsInfluenza, HumanMacrolidesAdultAgedATP Binding Cassette Transporter, Subfamily BAzithromycinCytochrome P-450 CYP3AErythromycinFemaleGenetic MarkersGenotypeHumansMaleMiddle AgedPharmacogeneticsABCB1 protein, humanAnti-Bacterial AgentsATP Binding Cassette Transporter, Subfamily BAzithromycinCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3AErythromycinGenetic MarkersMacrolidesABCB1adverse drug reactionsazithromycinCYP3A4macrolidespersonalized medicinePharmacogenetics

Identifiers

PMID39829075
PMCPMC11901476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.